COMMUNIQUÉS West-GlobeNewswire

Kraig Biocraft Laboratories Rings in the New Year with the Most Ambitious Genetic Engineering Program in its History
20/01/2026
ANN ARBOR, Mich., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today announced that it is [...]
Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026
20/01/2026
Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injury Participants to include people with Long COVID who [...]
Avacta Announces Year-end Trading Update
20/01/2026
LONDON and PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION ® , a tumor-activated oncology delivery platform, has [...]
Genvor, Inc. to Present at the 3rd Annual DealFlow Discovery Conference
20/01/2026
Woodland, CA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Genvor, Inc. (OTC: GNVR), a biotechnology company pioneering AI-accelerated peptide technology for sustainable agriculture, today announced that it will participate in the [...]
Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway
20/01/2026
BBI-940 IND accepted; initiation of first-in-human clinical trial on track for the first half of 2026 Portfolio prioritization, including discontinuation of POTENTIATE trial, extends operating runway into the second [...]
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
20/01/2026
VANCOUVER, British Columbia, Jan. 20, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class [...]
LIXTE Biotechnology Attending the DealFlow Discovery Conference, January 28-29
20/01/2026
BOCA RATON, Fla., Jan. 20, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical-stage pharmaceutical company advancing LB-100, a first-in-class inhibitor of [...]
Levicept Announces FDA Acceptance of IND Application for LEVI-04, a Potentially Disease-Modifying Treatment for Osteoarthritis
20/01/2026
SANDWICH, United Kingdom, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for osteoarthritis (OA), today announces the US Food [...]
smartbax in-licenses lead antibacterial compound targeting Gram-negative infections from Aicuris
20/01/2026
Munich, Germany, Jan. 20, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the in-licensing of a new compound class from [...]
Nicox annonce sa participation à des congrès au premier semestre 2026 et la présentation prochaine de données scientifiques
20/01/2026
Communiqué de presse Nicox annonce sa participation à des congrès au premier semestre 2026 et la présentation prochaine de données scientifiques 20 janvier 2026 – publication à 7H30 Sophia Antipolis, France Nicox SA ( [...]
Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations
20/01/2026
Press Release Nicox Announces Conference Attendance in H1 2026 and Upcoming Scientific Data Presentations January 20, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124 [...]
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
20/01/2026
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS 20 January 2026 at 08.30 EET Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion [...]
Nxera Pharma Establishes Metabolic Advisory Council to Advance Next-Generation Therapies for Obesity and Metabolic Disorders
20/01/2026
Council brings together leading global scientific and clinical experts in metabolic diseases to guide development of Nxera’s expanding proprietary pipeline Tokyo, Japan and Cambridge, UK, 20 January 2026 – Nxera Pharma [...]
Valneva fait un point sur son vaccin contre le chikungunya IXCHIQ®
19/01/2026
La Société retire volontairement ses demandes d’autorisation de mise sur le marché (BLA) et d’essais cliniques (IND) aux États-Unis Et continue d’évaluer le potentiel mondial du produit en fonction des besoins médicaux [...]
Valneva Provides Update on Chikungunya Vaccine IXCHIQ®
19/01/2026
Company voluntarily withdraws IXCHIQ BLA and IND in the U.S. Continuing review of global product opportunity according to medical need and commercial attractiveness Saint Herblain (France), January 19, 2026 – Valneva SE [...]
SAFE ORTHOPAEDICS FRANCHIT UNE ETAPE STRATEGIQUE : SIGNATURE DE SON PREMIER CONTRAT DE DISTRIBUTION AU BRESIL
19/01/2026
SAFE ORTHOPAEDICS FRANCHIT UNE ETAPE STRATEGIQUE : SIGNATURE DE SON PREMIER CONTRAT DE DISTRIBUTION AU BRESIL Fleurieux-sur-l’Arbresle – France – 19 janvier 2026 – 18h - Safe (FR001400ZU25 – ALSAF), annonce que sa [...]
Metabo Drops 2026 [Latest Update]: Is It Legit? Liquid Delivery Science, Ingredient Research, and Informed Consumer Analysis
19/01/2026
Consumer verification searches for Metabo Drops have intensified as "Is It Legit?" queries and ingredient transparency questions reshape how buyers evaluate liquid metabolism drops — this 2026 analysis examines safety [...]
Virbac: solid 2025 dynamic with annual revenue up +7.9% at CERS3; with strong momentum in key categories and countries
19/01/2026
Full-year 2025 revenue reached €1,465m : +7.9% at constant exchange rate and scope (CERS) vs 2024 +4.8% at actual rates impacted by significant currency headwinds, particularly in Latin America, IMEA and the Pacific. [...]
GUERBET : Bilan semestriel du contrat de liquidité
19/01/2026
Bilan semestriel du contrat de liquidité Villepinte, le 19 janvier 2026 : Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l’imagerie médicale, présente aujourd’hui le bilan [...]

Pages